DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL METHOD FOR THERAPEUTIC DRUG MONITORING OF AMIKACIN IN HUMAN PLASMA USING ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
DOI:
https://doi.org/10.22159/ijap.2024.v16s1.30Keywords:
Amikacin, Kanamycin, UPLC-MS/MS, Bioanalytical method, Human plasma, Validation, Therapeutic drug monitoringAbstract
Objective: The primary purposes of this research were to develop and validate a novel, accurate, sensitive, and repeatable bioanalytical method for determining amikacin in human plasma employing UPLC-MS/MS.
Methods: The bioanalytical procedure of amikacin involved a BEH C18 UPLC column as a stationary phase, with an employed mobile phase consisting of 0.1% v/v formic acid and acetonitrile (85:15 v/v). The flow rate was set at 0.1 ml/min, and the column temperature was kept at 30 °C. Kanamycin was selected as an internal standard. Amikacin and kanamycin were determined at mass-to-charge ratios (m/z) of 585.9>162.9 and 484.67>162.83, respectively. The amikacin bioanalysis method in the plasma matrix at the optimum separation condition was validated by determination of selectivity, linearity, accuracy, precision, recovery, carry-over, matrix effect, and stability.
Results: The optimum conditions of the sample preparation procedure were obtained through liquid-liquid extraction using trichloroacetic acid, followed by vortex mixing for one minute and centrifugation at 10,000 rpm for five minutes. Ten µl of supernatant was collected and injected into the system. A linear response was achieved in the 1.0-150.0 µg/ml range with R2 0.9997. Accuracy and precision met the requirements with % differences and coefficient variation at all concentration levels less than 15% and at the LLOQ level (1 μg/ml) less than 20%. The validated analytical method of amikacin in plasma is required for therapeutic monitoring in patients. The data would be valuable for determining or adjusting amikacin doses to enhance patient safety.
Conclusion: A bioanalytical method was developed and validated for determining amikacin in human plasma by UPLC-MS/MS. The method selectivity, linearity, accuracy, precision, recovery, carry-over, matrix effect, and stability were performed.
Downloads
References
Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R D. 2017;17(1):177-87. doi: 10.1007/s40268-016-0165-5, PMID 28063020.
Perez Blanco JS, Saez Fernandez EM, Calvo MV, Lanao JM, Martin Suarez A. Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: the role of albumin. Pharmaceutics. 2021;13(2):264. doi: 10.3390/pharmaceutics13020264, PMID 33672057.
Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53. doi: 10.1186/cc8945, PMID 20370907.
Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci. 2013;17(3):285-91. PMID 23426530.
Logre E, Enser M, Tanaka S, Dubert M, Claudinon A, Grall N. Amikacin pharmacokinetic/pharmacodynamic in Intensive Care Unit: a prospective database. Ann Intensive Care. 2020;10(1):75. doi: 10.1186/s13613-020-00685-5, PMID 32514769.
Sani RBM, Mohamad NB, Chlliah OAM, Azmi YB RR. Clinical pharmacokinetics pharmacy handbook. Vol. 2nd EDITIO, Ministry of Health Malaysia. Pharmacy practice and development division Ministry of Health lot 36. Jalan Universiti 46200 Petaling Jaya. Selangor, Malaysia; 2019. p. 25.
Chauhan B, Jalalpure S. Analysis of amikacin in human serum by UHPLC with fluorescence detector using chloro-formate reagent with glycine. Pharm Methods. 2016;7(2):99-103. doi: 10.5530/phm.2016.7.15.
Raut A, Sharma D, Suvarna VA. A status update on pharmaceutical analytical methods of aminoglycoside antibiotic: amikacin. Crit Rev Anal Chem. 2022 Feb 17;52(2):375-91. doi: 10.1080/10408347.2020.1803042, PMID 32781828.
Aliska G, Setiabudi R, Purwantyastuti, Karuniawati Anis, Sedono Rudyanto, Dewi Trisni Untari, K Azwar M. Optimal amikacin levels for patients with sepsis in intensive care unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. 2017;49:227-35.
Dewi TU, Instiaty Sedono, Rudyanto Aliska G. Kidney injury molecule-1 as an early amikacin-induced nephrotoxicity marker in patients with sepsis hospitalized in the Intensive Care Unit. Int J Appl Pharm. 2019:277-9.
Hasanah YIF, Harahap Y, Suryadi H. Development and validation method of cyclophosphamide and 4-hydroxycyclophosphamide with 4-hydroxycyclophosphamide-d4 as an internal standard in dried blood spots using UPLC-MS/MS. Int J App Pharm. 2021;13(2):148-52. doi: 10.22159/ijap.2021v13i2.39590.
Rao PTSRKP. HPLC method development and validation of lercanidipine HCl and atenolol, characterization of its degradants by LC-MS/MS. Int J Appl Pharm. 2022;14(2):125-34.
da Silva ACC, de Lima Feltraco Lizot L, Bastiani MF, Antunes MV, Brucker N, Linden R. Ready for TDM: simultaneous quantification of amikacin, vancomycin and creatinine in human plasma employing ultra-performance liquid chromatography-tandem mass spectrometry. Clin Biochem. 2019 Aug;70:39-45. doi: 10.1016/j.clinbiochem.2019.06.011, PMID 31228434.
Bijleveld Y, de Haan TR, Toersche J, Jorjani S, van der Lee J, Groenendaal F. A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;951-952(1):110-8. doi: 10.1016/j.jchromb.2014.01.035, PMID 24548921.
Harahap Y, Andriyani NH. Method development and validation of lercanidipine in human plasma by liquid chromatography tandem-mass spectrometry. Int J App Pharm. 2018 Jul 7;10(4):87. doi: 10.22159/ijap.2018v10i4.26544.
International Council For Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH. M10. In: Harmonised guideline bioanalytical method validation and study sample. Analysis; 2022. p. 1-59.
Matcha S, Chaudhari BB, Mallayasamy S, Lewis LE, Moorkoth S. Ion-pairing reagent free hydrophilic interaction LC-MS/MS method for therapeutic drug monitoring of amikacin in neonates. J App Pharm Sci. 2022. doi: 10.7324/JAPS.2023.62354.
Harahap Y, Steven S, Suryadi H. Development and validation of a UPLC-MS/MS method with volumetric absorptive microsampling to quantitate cyclophosphamide and 4-hydroxycyclophosphamide. Front Pharmacol. 2022;13:928721. doi: 10.3389/fphar.2022.928721, PMID 36034779.
US FDA (Food and Drug Administration), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation guidance for industry; 2018.
Xu L, Cheng X, Zhu G, Hu J, Li Q, Fan G. Therapeutic drug monitoring of amikacin: quantification in plasma by liquid chromatography-tandem mass spectrometry and work experience of clinical pharmacists. Eur J Hosp Pharm. 2022;29(e1):e77-82. doi: 10.1136/ejhpharm-2021-003049, PMID 34789474.
Alumuri T, Merugu K, Amarababu NLA, Kurnool A. Peramivir and related impurities in rat plasma and its applications in pharmacokinetic studies (bioanalytical method development and validation by LC-MS/MS). Int J App Pharm. 2022:53-61. doi: 10.22159/ijap.2022v14i5.45457.
Published
How to Cite
Issue
Section
Copyright (c) 2024 TRISWANTO SENTAT, HENNY LUCIDA, WIDYATI WIDYATI, HANSEN NASIF, YAHDIANA HARAHAP, PANDU HARIJONO, RATIH RATIH
This work is licensed under a Creative Commons Attribution 4.0 International License.
